Core VALUES
Unleash the potential
Patient centricity
Mycta community
Integrity
Vision & Mission
- Leading injectable pharmaceutical and biosimilar production.
- Operational excellence.
- Innovative & Commit on public health
- Internationally market growth by 2030.
- Strongly contribute on pharmaceutical efficiency by producing world-class injectable biosimilars and human plasma-derived products.
- Facilitate the care access for the patient.
Project timeline
Infrastructure Completed
Manufacturing building infrastructure finalized.
Initial Approval
Initial approval for pharmaceutical manufacturing granted.
Final Approval
Final regulatory approval obtained for operations.
Packaging Kickoff
Secondary packaging operations officially started.
Fill & Finish
Filling and finishing lines launched.
International Expansion
Full process integration and global rollout achieved.
Short-Term Objectives (2025-2027)
- Establishment of GMP-compliant manufacturing facilities
- Regulatory approvals for initial product portfolio
- Strategic supplier partnerships for key raw materials
- Build a skilled workforce of 224 employees
Long-Term Objectives (2027-2030)
- Expansion of biosimilar product portfolio
- Development of export capabilities for regional markets R&D
- investments for innovative formulations
- Establishing MYCTA as a leader in Biosimilar
LEADERSHIP TEAM
Our leadership team combines extensive pharmaceutical expertise with local market knowledge, bringing together diverse skills in medical science, pharmaceutical manufacturing, quality control, and business management.
Supported by expert consultants in GMP Compliance, Engineering, Quality Assurance, Regulatory Affairs, and Equipment Procurement.
STATE OF THE ART MANUFACTURING SITE
Organizational structure
MYCTA’s organizational structure is designed to support our injectable pharmaceutical focus with 224 skilled employees distributed across 9 specialized departments.
- General Management (5)
- Administration & Finance (55)
- Project Department (1)
- Technical & Regulatory Affairs (11)
- Industrial Operations (48)
- Quality Department (53)
- Engineering Department (42)
- Supply Chain & Logistics (27)
- Commercial Operations (8)
Skilled Workforce
224 highly trained employees with pharmaceutical expertise
Technical Focus
Strong emphasis on quality, operations and engineering
Knowledge Transfer
Expert consultants ensure world- class operational standards
AGRESSIF COMPETITIVE ADVANTAGES
Biotechnology Expertise
Specialized knowledge in biotechnology and advanced quality control techniques enables production of complex injectable biosimilars and human plasma-derived products.
Proactive & Strategic Market Access
Targeted approach to the biosimilar segment in Algeria, with products aligned with national health priorities and import substitution strategy.
Expert Leadership Team
Management team combines international pharmaceutical experience and mindset with deep local market knowledge, complemented by specialized consultants.
Win Win Partnerships
Collaborative relationship – Increased revenue or market share – Access to new customers or markets – Shared resources, knowledge, or expertise – Enhanced brand recognition or reputation – Cost savings or operational efficiencies – Innovation and problem-solving through combined strengths.
CONTACT US
Get in Touch
Our Location
Partner with Us
Interested in exploring partnership opportunities with
MYCTA? Our team is ready to collaborate with
international suppliers and partners.
- Contact us today to discuss potential collaborations